BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
6.93
+0.30 (4.52%)
At close: Oct 20, 2025, 4:00 PM EDT
6.90
-0.03 (-0.42%)
After-hours: Oct 20, 2025, 7:50 PM EDT
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts that cover BioCryst Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $19.55, which forecasts a 182.11% increase in the stock price over the next year. The lowest target is $11 and the highest is $30.
Price Target: $19.55 (+182.11%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 4 |
| Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 10 | 10 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +332.90% | Oct 15, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $24 → $26 | Buy | Maintains | $24 → $26 | +275.18% | Oct 15, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $17 → $27 | Buy | Maintains | $17 → $27 | +289.61% | Oct 15, 2025 |
| Needham | Needham | Strong Buy Maintains $17 → $20 | Strong Buy | Maintains | $17 → $20 | +188.60% | Oct 15, 2025 |
| Needham | Needham | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +145.31% | Aug 4, 2025 |
Financial Forecast
Revenue This Year
637.31M
from 450.71M
Increased by 41.40%
Revenue Next Year
671.31M
from 637.31M
Increased by 5.33%
EPS This Year
0.09
from -0.43
EPS Next Year
0.56
from 0.09
Increased by 538.48%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 662.7M | 737.1M | |||
| Avg | 637.3M | 671.3M | |||
| Low | 597.8M | 595.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 47.0% | 15.7% | |||
| Avg | 41.4% | 5.3% | |||
| Low | 32.6% | -6.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.20 | 0.96 | |||
| Avg | 0.09 | 0.56 | |||
| Low | 0.04 | 0.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 991.0% | |||
| Avg | - | 538.5% | |||
| Low | - | 246.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.